AstraZeneca (AZ) has announced that its fixed-duration Calquence (acalabrutinib)-based regimens have been approved by the European Commission (EC) to treat chronic lymphocytic leukaemia (CLL) in the ...

The EC has granted approval for a fixed-duration regimen of AstraZeneca's Calquence (acalabrutinib) plus venetoclax.

AstraZeneca PLC a annoncé vendredi que ses schémas thérapeutiques à durée fixe à base de Calquence ont été approuvés dans l'Union européenne pour le traitement des patients atteints ...

Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens of its chronic lymphocytic leukaemia candidate Calquence in a first-line ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced the European Union’s approval of its fixed-duration Calquence (acalabrutinib) regimens for the treatment of adult patients with previously ...

AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations A fixed-duration regimen of ...

A fixed-duration regimen of AstraZeneca’s Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, has been approved in the European Union (EU) for the treatment of ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) announced the European Union’s approval of its fixed-duration Calquence (acalabrutinib) regimens for the treatment of adult patients with previously untreated ...

(CercleFinance.com) - AstraZeneca annonce l'approbation par la Commission européenne d'un schéma thérapeutique à durée fixe de son traitement Calquence (acalabrutinib), en association avec le ...